Spondyloarthritis & psoriatic arthritis
Clinical and imaging outcomes of different phenotypes of axial spondyloarthritis: 5-year analysis of the DESIR cohort
Main finding · Disability (BASFI) over timeResult — go to the resultβ 0.4 95 % CI 0.2–0.7Authors' conclusion
Patients with 'axSpA at risk' show worse self-reported outcomes over time and are less likely to benefit from anti-inflammatory treatment than those with a classical axSpA phenotype.
Study context
- Population
- Patients with a clinical diagnosis of axial SpA (axSpA) from the DESIR cohort
- Participants
- 576 patients
- Exposure
- Three baseline axSpA phenotypes: 'At risk' and 'IBP+Peripheral' vs 'Axial'
- Outcome
- Disability (BASFI) over time
- Follow-up
- Up to 5 years
Methodological detailslatent class analysis, multivariable GEE models, 5-year follow-up
- Latent class analysis
- Multivariable GEE models
- 5-year follow-up
Main finding
As reported in the abstract
β
0.4
95 % CI 0.2–0.7
Observational data: associations, not effects.
Further findings
BASFI difference, At risk vs Axial, by bDMARD treatment (subgroup)
- β in patients receiving bDMARDs
- 0.6
- β in patients not receiving bDMARDs
- 0.5
- ∆BASFI in treated 'Axial'
- −1.3
- ∆BASFI in treated 'At risk'
- −0.9
BASFI difference by sex and HLA-B27 (subgroup)
- Difference mostly noted in female patients who were HLA-B27 positive
Original publication
Clinical and imaging outcomes of different phenotypes of axial spondyloarthritis: 5-year analysis of the DESIR cohort. Semin Arthritis Rheum. Published 2 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →